Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NMTC vs INM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
INM Captures Overall Composite Edge (35.6 SELL vs 45.5 HOLD), While NMTC Leads 4–2 on Growth & Valuation Pillars
INM Overall Winner
6-Pillar Tally: NMTC 4 – 2 INM
Matrix Metrics: NMTC 4 – 3 INM
As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. NMTC trades at $0.65 (N/M Forward P/E, -63.4% operating margin) versus INM at $15.56 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY).
- Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NMTC vs INM
NMTC
NeuroOne Medical Technologies Corporation Common Stock
$0.65
-3.38% 1D
Market Cap
$6.1M
TTM Revenue
$12M
Forward P/E
N/M
Beta / 30D Vol
1.55β · 105% Vol
Unified Composite Score
45.5
HOLD
Tech 33.0
Fund 51.0
Flow 60.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
INM
Head-to-Head Winner
InMed Pharmaceuticals Inc. Common Shares
$15.56
+17.79% 1D
Market Cap
$7.3M
TTM Revenue
$4.9M
Forward P/E
N/M
Beta / 30D Vol
-20.85β · 2208% Vol
Unified Composite Score
35.6
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (NMTC 4 – 2 INM)
1. Valuation Multiples
NMTC
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.3x
0.5x
2. Growth & Scale
NMTC
Revenue Growth (YoY)
+16.3%
-26.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$12M
$4.9M
Market Cap
$6.1M
$7.3M
3. Profitability & Quality
INM
Gross Margin
23.0%
34.5%
Operating Margin
-63.4%
0.0%
Net Profit Margin
-59.7%
0.0%
Return on Equity (ROE)
-124.7%
-222.1%
4. Balance Sheet & Cash Flow
NMTC
Cash Generation (TTM)
-$7.6M
-$7.5M
Cash Flow Margin
-60.7%
N/A
Net Cash / Leverage
$2.6M Net Cash
$4.7M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
NMTC
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
INM
OpEx & R&D Intensity
N/A
34.5% of Rev ($1.7M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NMTC (4) vs INM (3)| Institutional Metric | NMTC | INM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.1M | $7.3M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +16.3% | -26.2% | NMTC | |
| Operating Margin (TTM) | -63.4% | 0.0% | INM | |
| Net Profit Margin | -59.7% | 0.0% | INM | |
| Return on Equity (ROE) | -124.7% | -222.1% | NMTC | |
| 52-Week Range Position | 2% ($1–$5) | 94% ($1–$16) | INM | |
| Beta / 30D Volatility | 1.55β · 105% Vol | -20.85β · 2208% Vol | NMTC | |
| Unified Institutional Score | 45.5 / 100 (HOLD) | 35.6 / 100 (SELL) | NMTC | |
| Trailing 12M Revenue (USD) | $12M | $4.9M | Scale | |
| Gross Profit Margin (TTM) | 23.0% | 34.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | N/M PEG · 0.5x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$7.6M ($2.6M Net Cash) | -$7.5M ($4.7M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
INM +1088.53 pp
3M Horizon
INM +1047.2 pp
6M Horizon
INM +2375.38 pp
1Y Horizon
INM +1125.54 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NMTC Revenue | INM Revenue | NMTC Op. Margin | INM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2012 | $0M | N/A | -1491.1% | N/A | NMTC |
| FY2013 | $0M | N/A | -2009.0% | N/A | NMTC |
| FY2014 | $0M | N/A | -4646.1% | N/A | NMTC |
| FY2021 | $0M | $0M | -5735.9% | -535.9% | INM |
| FY2022 | $0M | $0M | -5860.2% | -1361.9% | INM |
| FY2023 | $0M | $0M | -612.3% | -192.2% | INM |
| FY2024 | $0M | $0M | -344.3% | -166.9% | INM |
| FY2025 | $10M | $0M | -46.5% | -165.1% | NMTC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NMTC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
INM
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact INM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NMTC Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
INM Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
34.5% of Rev ($1.7M)
90D Engineering Disclosures
0 Published
Investor FAQ NMTC vs INM Key Questions & Quantitative Answers
As of Nov 20, 2026, InMed Pharmaceuticals Inc. Common Shares (INM) captures the overall head-to-head institutional edge over NeuroOne Medical Technologies Corporation (NMTC) on higher Unified Composite conviction (35.6/100 SELL vs. 45.5/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMTC wins 4–2 across the 6-pillar growth and valuation breakdown. NMTC trades at $0.65 (N/M Forward P/E, -63.4% operating margin) versus INM at $15.56 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. INM 35.6/100 SELL), INM captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -63.4% operating margin) and revenue trajectory (-26.2% vs. +16.3% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile INM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 99.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with INM at -26.2% YoY revenue growth and +0.0% YoY earnings growth on $4.9M TTM revenue (34.5% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while INM shifted N/A. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 34.5% of Rev ($1.7M) (0 disclosures) for INM.
NMTC screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas INM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus INM (-222.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, INM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.85β · 2208% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
INM vs NMTC · Reverse Pair
NMTC vs IMMX
· Sector Peer
INM vs NUWE
· Sector Peer
INM vs QNRX
· Sector Peer
INM vs REVB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma